Fluid biomarkers in Alzheimer's disease - Current concepts

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Rosén, Christoffer ^a   Hansson, Oskar ^b   Blennow, Kaj ^a   Zetterberg, Henrik ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; Biomarker; Blood; Cerebrospinal fluid; Diagnosis; Disease stages; Phosphorylated tau; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BETA SECRETASE 1; BIOLOGICAL MARKER; CHITINASE; CHITINASE 3 LIKE 1 PROTEIN; CLUSTERIN; DESMOSTEROL; FLUORODEOXYGLUCOSE; GELATINASE A; HYPERPHOSPHORYLATED TAU PROTEIN; PREALBUMIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AUTOPSY; BLOOD ANALYSIS; BODY FLUID; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FRONTOTEMPORAL DEMENTIA; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; TAU PROTEINS;

EID: 84879083786     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-20     Document Type: Review

References (132)

1. Alzheimer's disease. Blennow K, de Leon MJ, Zetterberg H, Lancet 2006 368 387 403 10.1016/S0140-6736(06)69113-7 16876668 (Pubitemid 44108123)
2. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
3. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC, Neurology 2001 56 1143 1153 10.1212/WNL.56.9.1143 11342678 (Pubitemid 32405708)
4. Introduction to the recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH, Alzheimer's dementia j Alzheimer's Assoc 2011 7 257 262 10.1016/j.jalz.2011.03.004 23794572
5. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Blennow K, Hampel H, Weiner M, Zetterberg H, Nat Rev Neurol 2010 6 131 144 10.1038/nrneurol.2010.4 20157306
6. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Price JL, Morris JC, Ann Neurol 1999 45 358 368 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X 10072051 (Pubitemid 29120041)
7. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09) 70299-6 20083042
8. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Alzheimer's dementia j Alzheimer's Assoc 2011 7 280 292 10.1016/j.jalz.2011.03.003 23794572
9. An operational approach to national institute on aging-Alzheimer's association criteria for preclinical alzheimer disease. Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, et al. Ann Neurol 2012 71 765 775 10.1002/ana.22628 22488240
10. Alzheimer's disease: strategies for disease modification. Citron M, Nat Rev Drug Discov 2010 9 387 398 10.1038/nrd2896 20431570
11. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, et al. N Engl J Med 2012 367 795 804 10.1056/NEJMoa1202753 22784036
12. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, et al. Lancet Neurol 2012 11 1048 1056 10.1016/S1474-4422(12)70228-4 23137948
13. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Ringman JM, Coppola G, Elashoff D, Rodriguez-Agudelo Y, Medina LD, Gylys K, Cummings JL, Cole GM, Dement Geriatr Cogn Disord 2012 33 1 5 10.1159/000335729 22343824
14. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA, Neurology 2005 65 323 325 10.1212/01.wnl.0000171397. 32851.bc 16043812 (Pubitemid 41022387)
15. Biochemical markers in persons with preclinical familial Alzheimer disease. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, et al. Neurology 2008 71 85 92 10.1212/01.wnl.0000303973.71803.81 18509095
16. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K, J Neurol Neurosurg Psychiatry 2007 78 461 464 17098843 (Pubitemid 46662891)
17. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM, Arch Neurol 2007 64 343 349 10.1001/archneur.64.3. noc60123 17210801 (Pubitemid 46425688)
18. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E, Dement Geriatr Cogn Disord 2007 24 118 124 10.1159/000105017 17622715 (Pubitemid 47094071)
19. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E, Arch Neurol 2010 67 217 223 10.1001/archneurol.2009.316 20142530
20. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ, Neurology 2007 69 631 639 10.1212/01.wnl.0000267428.62582.aa 17698783 (Pubitemid 47256004)
21. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K, Dement Geriatr Cogn Disord 2003 15 169 176 10.1159/000068478 12584433 (Pubitemid 36206647)
22. Cerebrospinal fluid Abeta42 is the best predictor of clinical progression in patients with subjective complaints. van Harten AC, Visser PJ, Pijnenburg YA, Teunissen CE, Blankenstein MA, Scheltens P, van der Flier WM, Alzheimer's dementia j Alzheimer's Assoc 2012 23794572
23. Alzheimer's disease neuroimaging initiative I: increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Schott JM, Bartlett JW, Fox NC, Barnes J, Ann Neurol 2010 68 825 834 10.1002/ana.22315 21181717
24. Natural history of mild cognitive impairment in older persons. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J, Neurology 2002 59 198 205 10.1212/WNL.59.2.198 12136057 (Pubitemid 34779177)
25. Petersen RC, Mild cognitive impairment: aging to Alzheimer's disease Oxford; New York: Oxford University Press 2003 23760360
26. CSF markers for incipient Alzheimer's disease. Blennow K, Hampel H, Lancet Neurol 2003 2 605 613 10.1016/S1474-4422(03)00530-1 14505582 (Pubitemid 37162569)
27. Mild cognitive impairment as a diagnostic entity. Petersen RC, J Intern Med 2004 256 183 194 10.1111/j.1365-2796.2004.01388.x 15324362 (Pubitemid 39222988)
28. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L, Lancet Neurol 2006 5 228 234 10.1016/S1474-4422(06)70355-6 16488378 (Pubitemid 43238346)
29. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O, Arch Gen Psychiatry 2012 69 98 106 10.1001/archgenpsychiatry.2011.155 22213792
30. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O, J Alzheimer's disease JAD 2010 21 1119 1128 23792036
31. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, et al. Lancet Neurol 2009 8 619 627 10.1016/S1474-4422(09)70139-5 19523877
32. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Ann Neurol 2009 65 403 413 10.1002/ana.21610 19296504
33. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al. JAMA j Am Med Assoc 2009 302 385 393 10.1001/jama.2009.1064
34. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J, J Alzheimer's disease JAD 2011 24 537 546 23792036
35. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, et al. Alzheimer's dementia j Alzheimer's Assoc 2011 7 386 395 e386 10.1016/j.jalz.2011.05.2243 23794572
36. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's association global biomarkers consortium. Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, et al. Alzheimer's dementia j Alzheimer's Assoc 2013 9 137 140 10.1016/j.jalz.2012.11.003 23794572
37. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Blennow K, Vanmechelen E, Hampel H, Mol Neurobiol 2001 24 87 97 10.1385/MN:24:1-3:087 11831556 (Pubitemid 34066679)
38. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K, Neurosci Lett 2001 297 187 190 10.1016/S0304-3940(00)01697-9 11137759 (Pubitemid 32011305)
39. Neurochemical aftermath of amateur boxing. Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, et al. Arch Neurol 2006 63 1277 1280 10.1001/archneur.63.9.1277 16966505 (Pubitemid 44379829)
40. Elevated levels of Tau protein in cerebrospinal fluid of patients with probable creutzfeldt-jakob disease. Wang GR, Gao C, Shi Q, Zhou W, Chen JM, Dong CF, Shi S, Wang X, Wei Y, Jiang HY, et al. Am J Med Sci 2010 340 291 295 10.1097/MAJ.0b013e3181e92a1f 20881758
41. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. Blennow K, NeuroRx j Am Soc Exper NeuroTherap 2004 1 213 225 (Pubitemid 46589353)
42. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ, Exp Gerontol 2010 45 30 40 10.1016/j.exger.2009.10.010 19853650
43. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, et al. Arch Gen Psychiatry 2004 61 95 102 10.1001/archpsyc.61.1.95 14706948 (Pubitemid 38044645)
44. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Hakan W, Decraemer H, Nagga K, et al. Arch Neurol 2012 69 1445 1452 22925882
45. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM, Neurology 2012 78 47 54 10.1212/WNL. 0b013e31823ed0f0 22170879
46. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T, Arch Neurol 2009 66 382 389 10.1001/archneurol.2008.596 19273758
47. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H, Brain 2006 129 3035 3041 10.1093/brain/awl269 17012293 (Pubitemid 44684523)
48. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykko OT, Helisalmi S, Alafuzoff I, Hiltunen M, et al. Neurology 2012 78 1568 1575 10.1212/WNL.0b013e3182563bd0 22517093
49. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Strozyk D, Blennow K, White LR, Launer LJ, Neurology 2003 60 652 656 10.1212/01.WNL.0000046581.81650.D0 12601108 (Pubitemid 36246085)
50. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, et al. Ann Neurol 2006 59 512 519 10.1002/ana.20730 16372280 (Pubitemid 43358072)
51. PET imaging of amyloid deposition in patients with mild cognitive impairment. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A, Neurobiology of aging 2008 29 1456 1465 10.1016/j.neurobiolaging.2007.03.029 17499392
52. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Grimmer T, Riemenschneider M, Forstl H, Henriksen G, Klunk WE, Mathis CA, Shiga T, Wester HJ, Kurz A, Drzezga A, Biol Psychiatry 2009 65 927 934 10.1016/j.biopsych.2009. 01.027 19268916
53. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al. Neurology 2012 78 468 476 10.1212/WNL.0b013e3182477eed 22302554
54. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N, Neurosci Lett 2007 419 18 22 10.1016/j.neulet.2007.03.064 17482358 (Pubitemid 46694097)
55. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, et al. J Alzheimer's dis JAD 2007 12 255 260 23792036 (Pubitemid 350179256)
56. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H, J Alzheimer's dis JAD 2012 30 767 778 23792036
57. Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O, PLoS One 2009 4 6294 10.1371/journal.pone.0006294 19609443
58. Longitudinal stability of cerebrospinal fluid biomarker levels: fulfilled requirement for pharmacodynamic markers in Alzheimer's disease. Le Bastard N, Aerts L, Sleegers K, Martin JJ, Van Broeckhoven C, De Deyn PP, Engelborghs S, J Alzheimer's dis JAD 2013 33 807 822 23792036
59. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E, Int J Geriatr Psychiatry 2010 25 403 410 10.1002/gps.2353 19650161
60. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O, Neurology 2010 74 1531 1537 10.1212/WNL.0b013e3181dd4dd8 20458070
61. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. van Rossum IA, Vos SJ, Burns L, Knol DL, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, et al. Neurology 2012 79 1809 1816 10.1212/WNL.0b013e3182704056 23019259
62. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K, Arch Neurol 1999 56 673 680 10.1001/archneur.56.6.673 10369305 (Pubitemid 29266465)
63. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, et al. Arch Neurol 2008 65 1102 1107 10.1001/archneur.65.8.1102 18695061
64. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Hojrup P, Minthon L, Hansson O, Zetterberg H, et al. J Alzheimer's dis JAD 2013 33 1021 1032 23792036
65. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E, Mol chem neuropathol/spons Int Soc Neurochem World Feder Neurol res groups neurochem cerebrospinal fluid 1995 26 231 245 (Pubitemid 26002016)
66. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K, Neurosci Lett 2000 285 49 52 10.1016/S0304-3940(00)01036-3 10788705 (Pubitemid 30224621)
67. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D, DeBernardis J, Shen J, Moller HJ, Davies P, Hampel H, Neurosci Lett 2000 287 187 190 10.1016/S0304-3940(00)01178-2 10863026 (Pubitemid 30339380)
68. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K, Clin Chem 2005 51 336 345 10.1373/clinchem.2004.039347 15563479 (Pubitemid 40175803)
69. Alzheimer's Disease Neuroimaging I: Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Shaffer JL, Petrella JR, Sheldon FC, Choudhury KR, Calhoun VD, Coleman RE, Doraiswamy PM, Radiology 2013 266 583 591 10.1148/radiol.12120010 23232293
70. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Westman E, Muehlboeck JS, Simmons A, NeuroImage 2012 62 229 238 10.1016/j.neuroimage.2012.04.056 22580170
71. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, et al. Neurobiol aging 2012 33 2272 2281 10.1016/j.neurobiolaging.2011.12.017 22264648
72. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Schoonenboom NS, van der Flier WM, Blankenstein MA, Bouwman FH, Van Kamp GJ, Barkhof F, Scheltens P, Neurobiol aging 2008 29 669 675 10.1016/j.neurobiolaging.2006.11.018 17208336 (Pubitemid 351400823)
73. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, et al. J Alzheimer's dis JAD 2009 16 351 362 23792036
74. CSF biomarkers for Alzheimer's pathology and the effect size of APOE varepsilon4. Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, et al. Mol Psychiatry 2013
75. Increased beta-Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Holsinger RM, McLean CA, Collins SJ, Masters CL, Evin G, Ann Neurol 2004 55 898 899 10.1002/ana.20144 15174031 (Pubitemid 38702591)
76. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen EL, Hanemaaijer R, Clin Chem 2006 52 1168 1174 10.1373/clinchem.2006.066720 16614000 (Pubitemid 43794431)
77. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ, Neurology 2006 67 710 712 10.1212/01.wnl.0000229925.52203.4c 16924032 (Pubitemid 44273629)
78. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Zhong Z, Ewers M, Teipel S, Burger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y, Arch Gen Psychiatry 2007 64 718 726 10.1001/archpsyc.64.6.718 17548753 (Pubitemid 46878672)
79. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R, J Alzheimer's dis JAD 2010 20 253 260 23792036
80. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease. Rosen C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H, Neuromolecular Med 2012 14 65 73 10.1007/s12017-012-8171-4 22350541
81. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, Blennow K, Exp Neurol 2003 183 74 80 10.1016/S0014-4886(03)00027-X 12957490 (Pubitemid 37075858)
82. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Perneczky R, Tsolakidou A, Arnold A, Diehl-Schmid J, Grimmer T, Forstl H, Kurz A, Alexopoulos P, Neurology 2011 77 35 38 10.1212/WNL. 0b013e318221ad47 21700579
83. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, et al. Mol psychiatry 2010 15 138 145 10.1038/mp.2008.84 18663368
84. Cerebrospinal fluid soluble amyloid-beta protein precursor as a potential novel biomarkers of Alzheimer's disease. Lewczuk P, Popp J, Lelental N, Kolsch H, Maier W, Kornhuber J, Jessen F, J Alzheimer's dis JAD 2012 28 119 125 23792036
85. Correlations between soluble alpha/beta forms of amyloid precursor protein and Abeta38, 40, and 42 in human cerebrospinal fluid. Gabelle A, Roche S, Geny C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, et al. Brain res 2010 1357 175 183 20713025
86. Amyloid oligomers: formation and toxicity of Abeta oligomers. Sakono M, Zako T, FEBS J 2010 277 1348 1358 10.1111/j.1742-4658.2010.07568.x 20148964
87. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ, Nature 2002 416 535 539 10.1038/416535a 11932745 (Pubitemid 34288854)
88. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. Zempel H, Thies E, Mandelkow E, Mandelkow EM, J Neurosci 2010 30 11938 11950 10.1523/JNEUROSCI.2357-10.2010 20826658
89. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ, Proc Natl Acad Sci U S A 2011 108 5819 5824 10.1073/pnas.1017033108 21421841
90. Alzheimer's Disease-type neuronal tau hyperphosphorylation induced by a beta oligomers. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, et al. Neurobiol aging 2008 29 1334 1347 10.1016/j.neurobiolaging.2007.02.029 17403556 (Pubitemid 351970596)
91. Amyloid-beta oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM, Anal Biochem 2013 433 112 120 10.1016/j.ab.2012.09.014 23022042
92. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Nat Med 2008 14 837 842 10.1038/nm1782 18568035
93. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, et al. PLoS One 2010 5 15725 10.1371/journal.pone.0015725 21209907
94. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M, FASEB J 2010 24 2716 2726 10.1096/fj.09-150359 20339023
95. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA, Proc Natl Acad Sci U S A 2005 102 2273 2276 10.1073/pnas.0409336102 15695586 (Pubitemid 40279365)
96. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Pitschke M, Prior R, Haupt M, Riesner D, Nat Med 1998 4 832 834 10.1038/nm0798-832 9662376 (Pubitemid 28331026)
97. Amyloid-beta oligomer detection by enzyme-linked immunosorbent assay in cerebrospinal fluid and brain tissue. Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM, Anal Biochem 2012 433 112 120 23022042
98. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H, J Alzheimer's dis JAD 2012 29 171 176 23792036
99. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ, Alzheimers Dement 2013 9 99 112 10.1016/j.jalz.2012.11.005 23375565
100. Correlation of specific amyloid-beta oligomers with Tau in cerebrospinal fluid from cognitively normal older adults. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH, JAMA Neurol 2013 70 597 599
101. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, et al. The American journal of pathology 2008 173 130 143 10.2353/ajpath.2008.080045 18556781 (Pubitemid 351947961)
102. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. Biol Psychiatry 2010 68 903 912 10.1016/j.biopsych.2010.08.025 21035623
103. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K, Basun H, Annas P, Lannfelt L, Andreasen N, et al. J Alzheimer's dis JAD 2013 33 45 53 23792036
104. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, Roe CM, Peskind ER, Li G, Galasko DR, et al. PLoS One 2011 6 16032 10.1371/journal.pone.0016032 21264269
105. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S, Neuron 2006 49 489 502 10.1016/j.neuron.2006.01.022 16476660 (Pubitemid 43221886)
106. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, et al. Ann Neurol 2011 70 274 285 10.1002/ana.22448 21823155
107. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K, Brain research 2010 1362 13 22 20875798
108. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ 2nd, Ann Neurol 1998 44 410 413 10.1002/ana.410440322 9749613 (Pubitemid 28421451)
109. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, Blennow K, Zetterberg H, Wilson DH, Resuscitation 2013 84 351 356 10.1016/j.resuscitation.2012.07.027 22885094
110. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM, Arch Neurol 2000 57 100 105 10.1001/archneur.57.1.100 10634455 (Pubitemid 30027637)
111. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM, Lancet Neurol 2006 5 655 660 10.1016/S1474-4422(06)70501-4 16857570 (Pubitemid 44062411)
112. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD, Neurology 2003 61 1185 1190 10.1212/01.WNL.0000091890.32140.8F 14610118 (Pubitemid 37377535)
113. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD, Ann Neurol 1999 46 412 416 10.1002/1531-8249(199909)46: 3<412::AID-ANA19>3.0.CO;2-A 10482274 (Pubitemid 29416281)
114. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R, Proc Natl Acad Sci U S A 2008 105 14052 14057 10.1073/pnas.0805902105 18779561
115. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, et al. Arch Neurol 2008 65 256 263 10.1001/archneurol.2007.57 18268197 (Pubitemid 351240790)
116. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K, Neurobiol aging 2010 31 357 367 10.1016/j.neurobiolaging. 2008.03.027 18486992
117. Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, Chang YF, Tracy R, DeKosky ST, Neurology 2008 70 1664 1671 10.1212/01.wnl.0000306696.82017.66 18401021 (Pubitemid 351644132)
118. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG, Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377 (Pubitemid 46425689)
119. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB, JAMA j Am Med Assoc 2011 305 261 266 10.1001/jama.2010.1995
120. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F, Arch Neurol 2012 69 824 831 10.1001/archneurol.2011.1841 22451159
121. Biomarkers of Alzheimer disease in plasma. Irizarry MC, NeuroRx j Am Soc Exper NeuroTherap 2004 1 226 234 (Pubitemid 46591884)
122. Amyloid-beta peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. Laske C, Sopova K, Gkotsis C, Eschweiler GW, Straten G, Gawaz M, Leyhe T, Stellos K, J Alzheimer's dis JAD 2010 21 1263 1269 23792036
123. Blood-based protein biomarkers for diagnosis of alzheimer disease. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, et al. Arch Neurol 2012 69 1318 1325 10.1001/archneurol.2012.1282 22801742
124. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, et al. Nat Med 2007 13 1359 1362 10.1038/nm1653 17934472 (Pubitemid 350073592)
125. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, et al. Neurology 2012 79 897 905 10.1212/WNL.0b013e318266fa70 22855860
126. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O, PLoS One 2012 7 29868 10.1371/journal.pone.0029868 22279551
127. Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, Breteler M, Ann N Y Acad Sci 2009 1180 56 67 10.1111/j.1749-6632. 2009.05066.x 19906261
128. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y, J Lipid Res 2012 53 567 576 10.1194/jlr.M022376 22203775
129. Plasma transthyretin as a candidate marker for Alzheimer's disease. Velayudhan L, Killick R, Hye A, Kinsey A, Guntert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, et al. J Alzheimer's dis JAD 2012 28 369 375 23792036
130. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, Guntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM, NeuroImage 2012 59 212 217 10.1016/j.neuroimage.2011.07.056 21824521
131. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer's disease. Choi J, Lee HW, Suk K, J Neurol 2011 258 2181 2185 10.1007/s00415-011-6087-9 21562723
132. Investigation of matrix metalloproteinases, MMP-2 and MMP-9, in plasma reveals a decrease of MMP-2 in Alzheimer's disease. Lim NK, Villemagne VL, Soon CP, Laughton KM, Rowe CC, McLean CA, Masters CL, Evin G, Li QX, J Alzheimer's dis JAD 2011 26 779 786 23792036